Abstract
The treatment results for patients with Burkitt lymphoma have improved markedly over the past 20 years. Focus on the rapid doubling time of the lymphoma, and the frequent involvement of the central nervous system, have led to effective intensive chemotherapy regimens, where several of the drugs cross the blood-brain barrier. The overall survival is now 65-80% even when patients have advanced disease at the time of diagnosis. However, the condition and its complications such as tumour lysis syndrome are acute life threatening, and a quick diagnosis and proper management of complications are essential for the prognosis.
| Bidragets oversatte titel | Burkitt lymphoma is a highly malign tumour with a doubling time of twenty-four hours |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 173 |
| Udgave nummer | 43 |
| Sider (fra-til) | 2714-8 |
| Antal sider | 5 |
| ISSN | 0041-5782 |
| Status | Udgivet - 2011 |